Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mastectomy, Segmental | 5 | 2022 | 947 | 1.480 |
Why?
|
| Mesothelioma | 7 | 2019 | 814 | 1.130 |
Why?
|
| Refugees | 2 | 2023 | 494 | 1.080 |
Why?
|
| Breast Neoplasms | 11 | 2022 | 20448 | 0.970 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2022 | 1761 | 0.740 |
Why?
|
| Radiometry | 2 | 2022 | 800 | 0.680 |
Why?
|
| Asbestos | 1 | 2020 | 249 | 0.640 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2014 | 66 | 0.620 |
Why?
|
| Inflammasomes | 3 | 2016 | 460 | 0.590 |
Why?
|
| Lymphedema | 1 | 2022 | 500 | 0.530 |
Why?
|
| Pleural Neoplasms | 1 | 2020 | 604 | 0.510 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1165 | 0.490 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 258 | 0.480 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 2352 | 0.480 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 293 | 0.450 |
Why?
|
| Syria | 2 | 2023 | 78 | 0.440 |
Why?
|
| Radiosurgery | 1 | 2021 | 1266 | 0.430 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 513 | 0.420 |
Why?
|
| Doxorubicin | 3 | 2014 | 2224 | 0.410 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 2618 | 0.400 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 10879 | 0.380 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2334 | 0.380 |
Why?
|
| Quinazolines | 1 | 2014 | 1365 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 1536 | 0.300 |
Why?
|
| Piperidines | 1 | 2014 | 1565 | 0.290 |
Why?
|
| Lung Diseases | 1 | 2016 | 1905 | 0.280 |
Why?
|
| Pneumonia | 1 | 2016 | 2061 | 0.260 |
Why?
|
| Dentigerous Cyst | 1 | 2004 | 18 | 0.260 |
Why?
|
| Focal Infection, Dental | 1 | 2004 | 24 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 8896 | 0.260 |
Why?
|
| Mediastinitis | 1 | 2004 | 49 | 0.260 |
Why?
|
| Androgen Antagonists | 2 | 2023 | 1326 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2021 | 3449 | 0.250 |
Why?
|
| Mandibular Diseases | 1 | 2004 | 118 | 0.240 |
Why?
|
| Mastectomy | 2 | 2022 | 1752 | 0.240 |
Why?
|
| Silicon Dioxide | 2 | 2016 | 226 | 0.230 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 10926 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2021 | 933 | 0.220 |
Why?
|
| Seroma | 1 | 2022 | 67 | 0.210 |
Why?
|
| Turkey | 1 | 2022 | 236 | 0.210 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8577 | 0.210 |
Why?
|
| GPI-Linked Proteins | 2 | 2013 | 433 | 0.210 |
Why?
|
| Radiotherapy Dosage | 3 | 2022 | 2885 | 0.200 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 8644 | 0.190 |
Why?
|
| Spectrum Analysis | 1 | 2022 | 452 | 0.180 |
Why?
|
| Axilla | 1 | 2022 | 574 | 0.180 |
Why?
|
| Humans | 34 | 2023 | 725001 | 0.180 |
Why?
|
| Mucositis | 1 | 2020 | 103 | 0.180 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 12874 | 0.180 |
Why?
|
| Necrosis | 2 | 2021 | 1624 | 0.170 |
Why?
|
| Algorithms | 1 | 2019 | 13759 | 0.160 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 425 | 0.160 |
Why?
|
| Hormones | 1 | 2022 | 868 | 0.160 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 679 | 0.160 |
Why?
|
| Asbestos, Crocidolite | 2 | 2013 | 19 | 0.150 |
Why?
|
| Protons | 1 | 2022 | 1125 | 0.150 |
Why?
|
| Patients | 1 | 2022 | 830 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2022 | 1220 | 0.140 |
Why?
|
| Pulmonary Fibrosis | 1 | 2020 | 539 | 0.140 |
Why?
|
| Female | 17 | 2022 | 375303 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 177 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 578 | 0.130 |
Why?
|
| Genital Neoplasms, Female | 1 | 2021 | 508 | 0.130 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 335 | 0.130 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2014 | 40 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2020 | 542 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2022 | 74145 | 0.120 |
Why?
|
| Zeolites | 1 | 2013 | 5 | 0.120 |
Why?
|
| Transportation | 1 | 2015 | 213 | 0.120 |
Why?
|
| Breast | 1 | 2022 | 1914 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2020 | 1536 | 0.110 |
Why?
|
| Curcumin | 1 | 2014 | 99 | 0.110 |
Why?
|
| Brachytherapy | 1 | 2021 | 1244 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2022 | 3428 | 0.110 |
Why?
|
| Autocrine Communication | 1 | 2013 | 173 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2022 | 61674 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2167 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 1512 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2022 | 2682 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 1598 | 0.100 |
Why?
|
| Microspheres | 1 | 2013 | 783 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 686 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 57615 | 0.090 |
Why?
|
| Vaccination | 1 | 2022 | 3121 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2014 | 1799 | 0.090 |
Why?
|
| Piperazines | 1 | 2020 | 2482 | 0.090 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 929 | 0.090 |
Why?
|
| Aged | 9 | 2023 | 161379 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 1967 | 0.080 |
Why?
|
| Pyridines | 1 | 2020 | 2807 | 0.080 |
Why?
|
| Epithelium | 1 | 2013 | 1713 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11303 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 5342 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 3525 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2012 | 686 | 0.080 |
Why?
|
| Cell Survival | 2 | 2014 | 5908 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 16634 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 12795 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 9248 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 3948 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6527 | 0.070 |
Why?
|
| Particulate Matter | 1 | 2016 | 2457 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 1891 | 0.060 |
Why?
|
| Cytokines | 3 | 2014 | 7187 | 0.060 |
Why?
|
| Clindamycin | 1 | 2004 | 138 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 5458 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7835 | 0.060 |
Why?
|
| Male | 8 | 2023 | 346964 | 0.060 |
Why?
|
| RNA Interference | 1 | 2013 | 2957 | 0.060 |
Why?
|
| Mice, SCID | 3 | 2013 | 2727 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2014 | 8492 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2014 | 5041 | 0.060 |
Why?
|
| Sarcoma | 1 | 2014 | 1888 | 0.060 |
Why?
|
| Middle Aged | 8 | 2021 | 212155 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2004 | 325 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3225 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 2227 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 28718 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 51853 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2021 | 1604 | 0.050 |
Why?
|
| Quality of Life | 1 | 2022 | 12113 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2013 | 3575 | 0.050 |
Why?
|
| Risk Factors | 3 | 2022 | 70971 | 0.050 |
Why?
|
| Obesity | 1 | 2022 | 12420 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5088 | 0.040 |
Why?
|
| Radiodermatitis | 1 | 2019 | 60 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13563 | 0.040 |
Why?
|
| Lymphatic Irradiation | 1 | 2019 | 104 | 0.040 |
Why?
|
| Drainage | 1 | 2004 | 1124 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 5059 | 0.040 |
Why?
|
| Surface Properties | 1 | 2020 | 1167 | 0.040 |
Why?
|
| Apoptosis | 1 | 2014 | 9754 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2013 | 1892 | 0.040 |
Why?
|
| Glossectomy | 1 | 2017 | 52 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2020 | 1899 | 0.040 |
Why?
|
| Animals | 7 | 2020 | 168735 | 0.040 |
Why?
|
| Rectum | 1 | 2021 | 889 | 0.030 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 545 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2017 | 192 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 770 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 2896 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 19903 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2019 | 2976 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2014 | 216 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 426 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2013 | 258 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 295 | 0.030 |
Why?
|
| Time Factors | 3 | 2020 | 40178 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 20947 | 0.030 |
Why?
|
| Mesentery | 1 | 2012 | 205 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2012 | 332 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 627 | 0.030 |
Why?
|
| Adult | 4 | 2019 | 211523 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 341 | 0.020 |
Why?
|
| Rats | 2 | 2020 | 24422 | 0.020 |
Why?
|
| Mice | 5 | 2014 | 80318 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3601 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 5934 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18040 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 1660 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2360 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 3990 | 0.020 |
Why?
|
| Gadolinium | 1 | 2012 | 935 | 0.020 |
Why?
|
| Cisplatin | 1 | 2013 | 1622 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 3739 | 0.020 |
Why?
|
| Peritoneal Neoplasms | 1 | 2012 | 625 | 0.020 |
Why?
|
| Cattle | 1 | 2012 | 3951 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 6995 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 2078 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 6370 | 0.020 |
Why?
|
| Palliative Care | 1 | 2020 | 3359 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4799 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 5237 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13692 | 0.020 |
Why?
|
| Registries | 1 | 2020 | 7910 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 1948 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 2382 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3965 | 0.020 |
Why?
|
| Prevalence | 1 | 2020 | 14951 | 0.010 |
Why?
|
| Lung | 1 | 2022 | 9812 | 0.010 |
Why?
|
| Body Weight | 1 | 2013 | 4657 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15454 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 20743 | 0.010 |
Why?
|
| Logistic Models | 1 | 2017 | 13356 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10968 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 7859 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 24043 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 38720 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 7819 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 23178 | 0.010 |
Why?
|
| Macrophages | 1 | 2013 | 5693 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 13045 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10472 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8453 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 9375 | 0.010 |
Why?
|
| Inflammation | 1 | 2013 | 10337 | 0.010 |
Why?
|
| United States | 1 | 2021 | 68433 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 23445 | 0.010 |
Why?
|
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(8)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_